CNBC contributor Michael Santoli looks at companies with dividend yield that is higher than their corporate debt.» Read More
Nov 20- NovoCure Ltd said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23 percent in extended trading. NovoCure's therapy, Optune, which was evaluated in combination with Roche Holding AG's cancer drug, reduced the risk of death by 39 percent in patients, compared...
U.S. stocks closed more than 1 percent lower, pressured by a continued decline in oil prices and soft reports on the health of the consumer.
European equities finished sharply lower on Thursday, as oil prices and a fall in Rolls-Royce shares dented investor sentiment.
*Potential for technology highlighted at Berlin conference. FRANKFURT/ LONDON, Nov 12- A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology. Privately-held CureVac in the university town of...
Jim Cramer rattles off his take on caller favorite stocks, including this stock that is down so low it is ridiculous.
That could ease concern that if Allergan Inc's "friendly" talks with Pfizer Inc end in a merger, the combined company may not remain one of the world's largest inventors of new medicines. Pfizer refused to comment on Saunders' role in any potential deal with Allergan. Pfizer board member Dennis Ausiello, chief of medicine at Massachusetts General Hospital in...
*Q3 profit $1.23/ shr vs. est. Nov 5- Celgene Corp posted its smallest revenue growth in five quarters due to slower sales of its two key cancer drugs. Growing sales of expensive new cancer drugs and other treatments helped top U.S. drugmakers such as Pfizer Inc, Merck& Co and Bristol-Myers Squibb Co post stronger-than-expected quarterly profits last month.
Millennials invest less in the stock market than baby boomers do — and when they do, they're favoring very different stocks.
U.S. stocks closed lower, after a solid start to November, weighed by a decline in energy and more confidence in the possibility of a December hike.
Bone replacements, human tissue and prosthetics are being created by 3-D bioprinters. The science will soon be used to customize drugs.
These stocks are falling behind the S&P 500, and one technician says the underperformance is starting to look like 2000 and 2007.
Oct 27- Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments. Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.8 billion, which was just ahead of the $4.5 billion average Wall Street estimate, but little changed from...
Oct 27- A few months ago, Jenessa Torres watched her son erupt in hives after he licked a piece of nutty chocolate. "I'd definitely try it," said Torres, 31, a medical billing clerk in Manhattan. Leading the pack today are French company DBV Technologies SA and Brisbane, California- based Aimmune Therapeutics Inc..
NEW YORK, Oct 27- Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc, Merck& Co and Bristol-Myers Squibb Co to stronger-than-expected third-quarter profits. The results, announced on Tuesday, demonstrate that the "patent cliff" that had been hurting earnings as huge-selling drugs like Pfizer's...
Ken Frazier discussed drug pricing with the president, and he believes many in Washington have a "rational" view of the situation.
Some of the names on the move ahead of the open.
U.S. stock futures were searching for direction this morning. But things gear-up today, with lots of economic numbers and earnings as well as the start of the two-day Fed meeting.
Earnings news, especially from Apple, could stir up a market that's waiting for the Fed.
U.S. sovereign bonds traded higher on Monday ahead of the Federal Reserve's two-day policy meeting this week and a raft of major corporate earnings.
The "Halftime Report" traders give their top trades of the show.